Ardelyx, INC Form 4 insider transactions

Ardelix's CEO, Michael Raab, sold 2,310 shares of common stock at $6.59 per share on June 28, 2024, under a pre-arranged 10b5-1 trading plan.

Robert Blanks, Chief Regulatory and Quality Affairs Officer of Ardelix, Inc., sold 38,000 shares of common stock on June 21, 2024, under a pre-arranged 10b5-1 trading plan.

Director Richard J. Rodgers acquired shares and stock options in Ardelvx, Inc. under the company's Non-Employee Director Compensation Program.

Director Muna Bhanji acquired stock options in Ardelyx, Inc. on June 14, 2024, as part of the Non-Employee Director Compensation Program.

Director William C. Bertrand Jr. acquired 11,023 shares of common stock and options for 40,243 shares of common stock in Ardelvx, Inc. under the company's Non-Employee Director Compensation Program.

Director Onaiza Cadoret-Manier acquired stock options in Ardelix, Inc. on June 14, 2024, as part of the company's Non-Employee Director Compensation Program.

Director Robert B. Bazemore acquired stock options in Ardelix, Inc. on June 14, 2024.

Director David Mott reports acquisition of shares and stock options in Ardelyx, Inc. through a non-employee director compensation program.

Ardelvx CEO Michael Raab exercised stock options and sold 35,000 shares of common stock on June 13, 2024.

Laura A. Williams, Chief Medical Officer of Ardelvx, Inc., reports the exercise of stock options and subsequent sale of shares on June 5, 2024.

Chief Development Officer David P. Rosenbaum of Ardelvx, Inc. reports selling 17,872 shares of common stock at $7 on June 3, 2024.

Ardelvx CEO Michael Raab sold 7,500 shares of common stock on May 29, 2024, at an average price of $6.7187 per share, according to a Form 4 filing with the SEC.

Laura A. Williams, Chief Medical Officer of Ardelyx, Inc., sold shares of common stock to cover withholding taxes upon the vesting of restricted stock units.

David P. Rosenbaum, Chief Development Officer of Ardelyx, Inc., sold shares of common stock to cover withholding taxes upon the vesting of restricted stock units.

Susan Rodriguez, Chief Commercial Officer of Ardelyx, Inc., sold 6,703 shares of common stock to cover withholding taxes upon the vesting of restricted stock units.

Ardelyx's Chief Financial Officer, Justin Renz, sold 5,167 shares of common stock on May 21, 2024, to cover withholding taxes related to the vesting of restricted stock units.

Michael Raab, CEO of Ardelyx, Inc., reports the sale of shares to cover withholding taxes upon the vesting of restricted stock units, along with adjustments to beneficial ownership.

Elizabeth Grammer, Chief Legal and Administrative Officer of Ardelyx, Inc., reports selling shares to cover withholding taxes upon vesting of restricted stock units.

Robert Ora Felsch, SVP Finance and Chief Accounting Officer at Ardelyx, Inc., sold shares to cover withholding taxes upon the vesting of restricted stock units.

Robert Blanks, Chief Regulatory and Quality Affairs Officer at Ardelvx, sold 4,855 shares of common stock to cover withholding taxes upon the vesting of restricted stock units.

Ardelix CEO Michael Raab sold 3,000 shares of common stock at $7.99 per share on May 14, 2024, under a pre-arranged 10b5-1 trading plan.

Robert Felsch, SVP Finance and Chief Accounting Officer of Ardelvx, Inc., reports the acquisition and disposal of common stock and stock options.

Elizabeth A. Grammer, Chief Legal and Administrative Officer of Ardelvx, Inc., reports exercising stock options and selling shares of common stock on May 6, 2024.

Elizabeth Grammer, Chief Legal and Administrative Officer of Ardelvx, Inc., sold 45,000 shares of common stock at $9 per share on May 3, 2024, under a pre-arranged 10b5-1 trading plan.

Laura A. Williams, Chief Medical Officer of Ardelvx Inc., exercised stock options and sold shares on May 3, 2024, according to a Form 4 filing with the SEC.

Ardelvx's CEO, Michael Raab, exercised stock options and sold 30,000 shares of common stock at an average price of $6.4019, according to a Form 4 filing.

Ardelix's CEO, Michael Raab, sold 7,500 shares of common stock at an average price of $7.0565 on April 15, 2024, under a pre-arranged 10b5-1 trading plan.

Michael Raab, President and CEO of Ardelyx, Inc., reports the sale of 1,518 shares of common stock at $7.31 per share under a pre-arranged 10b5-1 trading plan.

Mike Kelliher, Executive Vice President at Ardelix, reports acquiring 160,000 shares of common stock and stock options for 205,000 shares on March 25, 2024.

Robert Blanks, Chief Regulatory and Quality Affairs Officer at Ardelvx, reports gifting 1,000 common shares on March 15, 2024.